As of June 21, 2025, 4D Pharma PLC (DDDD.L) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing 4D Pharma PLC's Forward P/E to Peers
To better understand 4D Pharma PLC's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| 4D Pharma PLC (DDDD.L) | - |
| Dechra Pharmaceuticals PLC (DPH.L) | 3038.99 |
| AstraZeneca PLC (AZN.L) | 1614.39 |
| Alliance Pharma PLC (APH.L) | 1284.82 |
| Hikma Pharmaceuticals PLC (HIK.L) | 1234.85 |
| Indivior PLC (INDV.L) | 1050.61 |
Compared to its competitors, 4D Pharma PLC's Forward P/E is difficult to compare due to insufficient data.